Today's 3 Worst Stocks

All in all, not a bad day for the S&P 500 Index (SNPINDEX: ^GSPC  ) , which rose to an all-time high today. Markets gained ahead of a two-day Federal Reserve meeting that begins tomorrow -- the sentiment seems to be that Chairman Ben Bernanke and the rest of the committee will continue their bond-buying program, injecting more money into the U.S. economy. That's all well and good for the markets, but the growth didn't translate to today's three major S&P laggards.

Just after the craziness of tax season, you might expect H&R Block (NYSE: HRB  ) shares to be doing just fine. Instead, its stock slipped 2.5% after investors showed serious concerns with the number of tax returns the company has prepared this year. Flat year-over-year returns means H&R Block hasn't shown it can take market shares from ambitious and prevalent competition.

Retail companies took a hit today, and shares of Kohl's (NYSE: KSS  ) lost 2% after a streak of cold weather is set to hit business. Most of the cold weather setbacks are happening in the Northeast, and Kohl's has a large portion of its business in the region. With people not venturing outdoors as much when temperatures plummet, shareholders could be in for a nasty surprise come the earnings announcement May 16. 

The last of the day's laggards, Abbott Laboratories spinoff AbbVie (NYSE: ABBV  ) , lost 1.3% Monday. Shares may have simply sold off after shares bounced on Friday, when quarterly results beat expectations. Though revenue only added a little less than 4%, the sales growth in the company's primary moneymaker, Humira, surged 16%. The CEO was tough on the company's results Friday, criticizing the effect of patent expirations on results. Today, the market realized that those concerns may be a little more material than previously expected.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2395481, ~/Articles/ArticleHandler.aspx, 7/28/2014 2:23:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement